Tesamorelin + Ipamorelin

Tesamorelin is FDA-approved for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, based on Phase 3 clinical trial data. Its use for body composition and metabolic health in non-HIV populations is off-label. Ipamorelin has not been independently approved by the FDA. Both compounds can only be prescribed through licensed clinicians where state law allows.

Tesamorelin has one of the strongest clinical evidence bases of any peptide in this category, with multiple randomized, placebo-controlled trials published in the New England Journal of Medicine and JAMA documenting significant reductions in visceral fat, triglycerides, and cholesterol ratios. A secondary analysis of Phase 3 trial data also showed improvements in skeletal muscle area and density. Ipamorelin's human research base is smaller and earlier-stage, with its profile primarily established through preclinical work and early clinical studies. The combination as a stack has not been the subject of a dedicated clinical trial.

The combination is designed to stimulate a stronger, more complete growth hormone signal than either compound achieves alone. Tesamorelin drives a sustained physiologic GH pulse through the GHRH pathway; Ipamorelin amplifies that pulse through a separate ghrelin receptor pathway, without raising cortisol or prolactin. The downstream effects include support for visceral fat reduction, lean muscle preservation, tissue repair, and the kind of deep slow-wave sleep that is essential for overnight recovery. Most patients begin noticing changes in sleep quality and energy within the first few weeks, with body composition changes becoming more apparent over several months of consistent use.

Both compounds are generally well-tolerated at clinical doses under physician supervision. Tesamorelin's safety profile is well-documented through its FDA approval process and post-market use. Ipamorelin's selective receptor profile means fewer hormonal side effects than older GH secretagogues. Because Tesamorelin can affect IGF-1 and blood sugar levels, routine lab monitoring is standard at AIRA. Your prescribing clinician will review your health history and labs before starting and at regular intervals throughout your protocol.

Tesamorelin + Ipamorelin is not recommended for individuals who are pregnant or breastfeeding. It is also contraindicated for those with active or suspected malignancy, uncontrolled diabetes or significant insulin resistance, proliferative diabetic retinopathy, or known hypersensitivity to either compound. Patients with a history of certain endocrine conditions should discuss their individual situation with their prescribing clinician before starting. Your AIRA physician will review your full health history and baseline labs to determine whether this protocol is appropriate for you.

Both compounds are administered via subcutaneous injection, typically in the evening to align with the body's natural overnight growth hormone pulse. Your AIRA clinician will determine the appropriate protocol based on your health history, goals, and lab results. AIRA does not provide specific dosing guidance on this page; all protocols are determined by your prescribing physician.

Tesamorelin + Ipamorelin can be part of a broader wellness or optimization protocol, depending on your goals and current health status. It is often considered alongside other metabolic or recovery-focused therapies. Because Tesamorelin affects the GH axis and IGF-1, your clinician will evaluate any potential interactions with other hormone therapies or peptides before recommending additions to your protocol.